Drugs / High-activity natural killer
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03007875 | Dec 2016 → Dec 2017 | non-small cell lung carcinoma | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
| Phase 1/2 | NCT03007823 | Dec 2016 → Dec 2017 | melanoma | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
| Phase 1/2 | NCT03008304 | Dec 2016 → Dec 2017 | malignant pancreatic neoplasm | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
| Phase 1/2 | NCT03007836 | Dec 2016 → Dec 2017 | nasopharyngeal carcinoma | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
| Phase 1/2 | NCT03008499 | Dec 2016 → Dec 2017 | colorectal cancer | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
| Phase 1/2 | NCT03008330 | Dec 2016 → Dec 2017 | tongue cancer | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | High-activity natural killer | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03008330 ↗ |
| Known as | HANK | “In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies.” NCT03008330 ↗ |
| Modality | Cell therapy | “high-activity natural killer cells” NCT03007823 ↗ |
| Route | Intravenous | “i.v.” NCT03007823 ↗ |